Janney Montgomery Scott LLC decreased its stake in shares of ZIOPHARM Oncology Inc (NASDAQ:ZIOP) by 10.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 238,662 shares of the biotechnology company’s stock after selling 27,704 shares during the period. Janney Montgomery Scott LLC’s holdings in ZIOPHARM Oncology were worth $1,484,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Norges Bank purchased a new stake in ZIOPHARM Oncology during the fourth quarter valued at about $5,556,000. Vanguard Group Inc. raised its stake in ZIOPHARM Oncology by 5.7% in the first quarter. Vanguard Group Inc. now owns 7,310,537 shares of the biotechnology company’s stock valued at $46,348,000 after buying an additional 396,678 shares in the last quarter. Morgan Stanley raised its stake in ZIOPHARM Oncology by 19.5% in the first quarter. Morgan Stanley now owns 1,989,175 shares of the biotechnology company’s stock valued at $12,610,000 after buying an additional 324,774 shares in the last quarter. California Public Employees Retirement System raised its stake in ZIOPHARM Oncology by 95.9% in the first quarter. California Public Employees Retirement System now owns 435,532 shares of the biotechnology company’s stock valued at $2,541,000 after buying an additional 213,166 shares in the last quarter. Finally, Iridian Asset Management LLC CT purchased a new stake in ZIOPHARM Oncology during the first quarter valued at about $1,187,000. 38.20% of the stock is currently owned by institutional investors and hedge funds.

Shares of ZIOPHARM Oncology Inc (ZIOP) opened at 5.72 on Thursday. ZIOPHARM Oncology Inc has a 52-week low of $4.84 and a 52-week high of $7.88. The firm’s market capitalization is $804.42 million. The company’s 50 day moving average price is $5.96 and its 200 day moving average price is $6.34.

ZIOPHARM Oncology (NASDAQ:ZIOP) last announced its quarterly earnings results on Monday, July 31st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. ZIOPHARM Oncology’s quarterly revenue was down 5.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.01) EPS. Analysts forecast that ZIOPHARM Oncology Inc will post ($0.54) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/janney-montgomery-scott-llc-lowers-position-in-ziopharm-oncology-inc-ziop/1467961.html.

ZIOP has been the topic of several research reports. Zacks Investment Research raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, April 26th. HC Wainwright initiated coverage on ZIOPHARM Oncology in a research report on Thursday, June 1st. They set a “buy” rating and a $9.50 price target on the stock. ValuEngine raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Monday, July 17th. Finally, BidaskClub raised ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday. Five analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $13.17.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

Want to see what other hedge funds are holding ZIOP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZIOPHARM Oncology Inc (NASDAQ:ZIOP).

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.